TXUE - ETF AI Analysis
Top Page
Thornburg International Equity ETF (TXUE)
TXUE, the Thornburg International Equity ETF, has a solid overall rating driven by high-quality holdings like AstraZeneca, Roche, and BNP Paribas, which combine strong financial performance, positive outlooks, and generally attractive valuations. The fund also holds several stable but more mixed names such as Orange and E.ON, where weaker revenue growth, cash flow challenges, or neutral-to-bearish technical trends slightly weigh on the rating. A key risk factor is its concentration in large international financial and utility companies, where issues like high leverage, cash flow pressures, or overbought conditions could impact future returns.
TXUE vs. SPDR S&P 500 ETF (SPY)
- AUM
- 582.32M
- Region
- Developed Markets
- Expense Ratio
- 0.65%
- Beta
- 0.62
- Issuer
- Thornburg
- Inception Date
- Jan 21, 2025
- Dividend Yield
- 0.98%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
TXUE Summary
Thornburg International Equity ETF (TXUE) is a global stock fund that invests in companies outside the U.S., without tracking a specific index. It spreads money across many countries like France, Japan, Germany, and the UK, and across different industries such as industrials, finance, health care, and energy. Well-known holdings include AstraZeneca and Sony. Someone might invest in TXUE to diversify beyond the U.S. market and tap into growth from both developed and emerging economies. A key risk is that international stocks can be volatile and may move differently from the U.S. market, so the value of the ETF can go up and down.
How much will it cost me?
This ETF has an expense ratio of 0.65%, which means you’ll pay about $6.50 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed, with a team selecting international stocks rather than simply tracking an index.
What would affect this ETF?
TXUE could benefit if developed markets outside the U.S. grow steadily, especially in industrials, financials, energy, and health care, helping major holdings like AstraZeneca, TotalEnergies, and European banks perform well. On the downside, slower global growth, higher interest rates, or stricter regulations in Europe and Japan could hurt banks, utilities, and energy companies, while currency swings between foreign markets and the U.S. could add extra volatility to returns.
TXUE Top 10 Holdings
TXUE leans heavily into European financials and energy, with names like TotalEnergies and Roche acting as key engines for recent gains, both showing rising momentum and solid fundamentals. Sony adds a touch of Japan and has been climbing lately, even if its year-to-date story is more mixed. On the other side of the ledger, AstraZeneca and BNP Paribas have been lagging, occasionally pulling on the fund’s overall performance. With a clear developed-markets ex-U.S. focus, TXUE is a global traveler that largely skips the U.S. and concentrates its bets in Europe and Japan.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 FR:TTE | TotalEnergies SE | 3.03% | $17.59M | EUR 190.70B | 59.27% | 78Outperform |
 FR:ORA | ORANGE SA | 2.94% | $17.06M | EUR 38.47B | 4.44% | 65Neutral |
 NL:INGA | ING GROEP | 2.84% | $16.54M | EUR 78.77B | 27.71% | 61Neutral |
 DE:EOAN | E.ON SE | 2.84% | $16.51M | EUR 49.40B | 15.84% | 61Neutral |
 NL:NN | NN Group N.V. | 2.83% | $16.43M | EUR 19.59B | 29.72% | 68Neutral |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 FR:BNP | BNP Paribas | 2.80% | $16.30M | EUR 94.61B | 28.86% | 77Outperform |
 IT:ENEL | Enel S.p.A. | 2.76% | $16.06M | EUR 92.44B | 5.93% | 67Neutral |
 JP:8316 | Sumitomo Mitsui Financial Group | 2.72% | $15.82M | JPY 24.48T | 56.38% | 77Outperform |
TXUE Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TXUE, the sentiment is Negative. The current price of 34.70 is above the 20-day moving average (MA) of 34.66, below the 50-day MA of 35.29, and above the 200-day MA of 34.38, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 46.32 is Neutral, neither overbought nor oversold. The STOCH value of 61.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TXUE.
TXUE Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| TXUE | $34.70 | $37.00(6.63% Upside) | $582.32M | 0.65% | 64Neutral |
 FYLD | $40.16 | $43.46(8.21% Upside) | $753.10M | 0.59% | 62Neutral |
 AVSD | $78.61 | $91.49(16.38% Upside) | $376.48M | 0.23% | 65Neutral |
 DXIV | $71.90 | $84.10(16.97% Upside) | $232.54M | 0.30% | 62Neutral |
 NBIE | $26.42 | $31.46(19.10% Upside) | $233.80M | 0.29% | 70Outperform |
 RINT | $31.64 | $38.99(23.23% Upside) | $166.97M | 0.49% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TXUE | Thornburg International Equity ETF | 34.70 | 4.74 | 15.83% | |
| FYLD | Cambria Foreign Shareholder Yield ETF | 40.16 | 10.06 | 33.40% | |
| AVSD | Avantis Responsible International Equity ETF | 78.61 | 8.63 | 12.33% | |
| DXIV | Dimensional International Vector Equity ETF | 71.90 | 11.99 | 20.01% | |
| NBIE | Neuberger International Core Equity ETF | 26.41 | 1.54 | 6.20% | |
| RINT | International Developed Equity Active ETF | 31.64 | 3.62 | 12.93% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.